Journal ArticleDOI
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
William J. Sandborn,Stephen B. Hanauer,Seymour Katz,Michael Safdi,Douglas G. Wolf,Richard D. Baerg,William J. Tremaine,Therese Johnson,Nancy N. Diehl,Alan R. Zinsmeister +9 more
Reads0
Chats0
TLDR
Subcutaneous etanercept at a dose of 25 mg twice weekly is safe, but not effective, for the treatment of patients with moderate to severe Crohn's disease.About:
This article is published in Gastroenterology.The article was published on 2001-11-01. It has received 918 citations till now. The article focuses on the topics: Infliximab & Etanercept.read more
Citations
More filters
Journal ArticleDOI
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
TL;DR: The current diagnostic approach, their pathology, natural course, and common complications, the assessment of disease activity, extraintestinal manifestations, and medical and surgical management are discussed, and diagnostic and therapeutic algorithms are provided.
Journal ArticleDOI
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
Stephen B. Hanauer,William J. Sandborn,Paul Rutgeerts,Richard N. Fedorak,Milan Lukas,Donald G. MacIntosh,Remo Panaccione,Douglas C. Wolf,Paul F. Pollack +8 more
TL;DR: Adalimumab was superior to placebo for induction of remission in patients with moderate to severe Crohn's disease naive to anti-TNF therapy and was well tolerated.
Journal ArticleDOI
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
TL;DR: The biology of T NF and related family members are discussed in the context of the potential mechanisms of action of TNF antagonists in a variety of immune-mediated inflammatory diseases.
Journal ArticleDOI
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber,Bruce E. Sands,Steve Lewitzky,Marc Vandemeulebroecke,Walter Reinisch,Peter D.R. Higgins,Jan Wehkamp,Brian G. Feagan,Michael D Yao,Marek Karczewski,Jacek Karczewski,Nicole Pezous,Stephan Bek,Gerard Bruin,Bjoern Mellgard,Claudia Berger,Marco Londei,Arthur P. Bertolino,Gervais Tougas,Simon Travis +19 more
TL;DR: Blockade of IL-17A was ineffective and higher rates of adverse events were noted compared with placebo, and unfavourable responses on secukinumab were driven by patients with elevated inflammatory markers.
References
More filters
Journal ArticleDOI
Development of a Crohn's Disease Activity Index: National Cooperative Crohn's Disease Study
TL;DR: In this paper, a multiple regression computer program was utilized to derive an equation for prediction of the physician's over-all ratings from a subset of the predictor variables fulfilling a combination of constraints.
Journal ArticleDOI
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Peter E. Lipsky,D. van der Heijde,E W St Clair,Daniel E. Furst,F. C. Breedveld,J. R. Kalden,Josef S. Smolen,M Weisman,Paul Emery,Marc Feldmann,Gregory Harriman,Ravinder Nath Maini +11 more
TL;DR: In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotRexate provided clinical benefit and halted the progression of joint damage.
Journal ArticleDOI
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
Stephan R. Targan,Stephen B. Hanauer,S. J. H. Van Deventer,Lloyd Mayer,Daniel H. Present,T. Braakman,K. L. Dewoody,T. F. Schaible,Paul Rutgeerts +8 more
TL;DR: A 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 patients with moderate-to-severe Crohn's disease that was resistant to treatment, finding clinical response, the primary end point, was a reduction of 70 or more points in the score on theCrohn's Disease Activity Index at four weeks.
Journal ArticleDOI
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Daniel H. Present,Paul Rutgeerts,Stephan R. Targan,Stephen B. Hanauer,Lloyd Mayer,R. A. van Hogezand,Daniel K. Podolsky,Bruce E. Sands,T. Braakman,K. L. Dewoody,Th.F. Schaible,S. J. H. Van Deventer +11 more
TL;DR: Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease and the most common adverse events for patients treated with infliximab were headache, abscess, upper respiratory tract infection, and fatigue.
Journal ArticleDOI
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Ravinder N. Maini,E W St Clair,F. C. Breedveld,Daniel E. Furst,Joachim R. Kalden,Michael H. Weisman,Josef S. Smolen,Paul Emery,G Harriman,Marc Feldmann,Peter E. Lipsky +10 more
TL;DR: Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group.